Dataset from A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009928
下载链接
链接失效反馈官方服务：
资源简介：
Background:
- Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets
CD22, a molecule on the surface of essentially all hairy cell leukemia cells. Moxetumomab
pasudotox binds to CD22, goes into the cell, and releases a toxin which kills the cell. In a
phase I trial it had activity in relapsed/refractory hairy cell leukemia with safety profile
supporting further clinical study (http://ncbi.nlm.nih.gov/pubmed/22355053). This is a phase
III multicenter trial designed to confirm these results.
创建时间：
2025-02-27
